Adjuvatis, a French startup in biotechnology, develops innovative safe-by-design delivery systems to help laboratories and pharmaceutical companies in vaccine formulation as adjuvants and in drug delivery as vectors for oncology, dermatology, infections, etc.
Our first technology, called i-Particles®, is based on 200 nm-diameter particles composed of poly-lactic acid only (any surfactant and solvents) for formulation of hydrophobic molecules in the particle core and surface functionalization of peptides. Our second technology, i-LipoP®, consists in i-Particles® covered by lipidic bilayers at their surface for vectorization of nucleic acids and peptides.
Company Details
- Employees
- 4
- Founded
- -
- Address
- 60, Avenue Rockefeller, Bâtiment Laënnec,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- adjuvatis.com
- HQ
- Lyon, Auvergne-Rhône-Alpes
Adjuvatis Questions
Adjuvatis's website is adjuvatis.com
Adjuvatis's LinkedIn profile is https://fr.linkedin.com/company/adjuvatis
Adjuvatis has
4 employees.
View email and phone details for 4
employees at Adjuvatis.
Adjuvatis's industry is
Biotechnology Research
Adjuvatis's top competitors are
Axoltis Pharma,
Anaquant,
Enyo Pharma,
Biotem First Class Antibodies & Immunoassays,
Advanced Biodesign,
Cynbiose,
Osivax,
Eurofins Calixar,
Adocia,
Genoway.
Adjuvatis's categories are Biotechnology Research
Adjuvatis's founding year is 2013
